gemcitabine has been researched along with talaporfin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abo, T; Isomoto, H; Nagayasu, T; Nanashima, A; Nonaka, T; Nonaka, Y; Uehara, M | 1 |
| Fuse, T; Ozeki, T; Tagami, T; Tane, M | 1 |
2 other study(ies) available for gemcitabine and talaporfin
| Article | Year |
|---|---|
Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Organoplatinum Compounds; Oxaliplatin; Photochemotherapy; Photosensitizing Agents; Porphyrins; Proliferating Cell Nuclear Antigen; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Effective light-triggered contents release from helper lipid-incorporated liposomes co-encapsulating gemcitabine and a water-soluble photosensitizer.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Deoxycytidine; Drug Compounding; Drug Liberation; Female; Gemcitabine; Infrared Rays; Kinetics; Lipids; Liposomes; Mice; Photosensitizing Agents; Porphyrins; Solubility; Technology, Pharmaceutical; Water | 2018 |